Glutathione transferase-A2 s112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation

Haematologica

Volumn 99, Issue 1, 2014, Pages 172-179

  Bonifazi, Francesca ^a   Storci, Gianluca ^a,b   Bandini, Giuseppe ^a   Marasco, Elena ^a   Dan, Elisa ^a   Zani, Elena ^a   Albani, Fiorenzo ^b   Bertoni, Sara ^a   Bontadini, Andrea ^a   De Carolis, Sabrina ^b   Sapienza, Maria Rosaria ^b   Rizzi, Simonetta ^a   Motta, Maria Rosa ^a   Ferioli, Martina ^a   Garagnani, Paolo ^a   Cavo, Michele ^a   Mantovani, Vilma ^a   Bonafè, Massimiliano ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; BILIRUBIN; BUSULFAN; CELL LINE, TUMOR; CYTOKINES; FEMALE; GENOTYPE; GLUTATHIONE TRANSFERASE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFLAMMATION MEDIATORS; ISOENZYMES; LIVER; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892588980     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.089888     Document Type: Article

References (45)

1. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, et al. Marrow transplantation for acute nonlym-phocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309(22):1347-1353.
2. Hansen JA, Chien JW, Warren EH, Zhao LP, Martin PJ. Defining genetic risk for graft-ver-sus-host disease and mortality following allogeneic hematopoietic stem cell transplantation. Curr Opin Hematol. 2010;17(6): 483-492.
3. Chien JW, Zhang XC, Fan W, Wang H, Zhao LP, Martin PJ, et al. Evaluation of published single nucleotide polymorphisms associated with acute graft versus host disease. Blood. 2012;119(22):5311-5319.
4. Mullally A, Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood. 2007;109(4):1355-1362.
5. Hansen JA, Petersdorf EW, Lin MT, Wang S, Chien JW, Storer B, et al. Genetics of allo-geneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes. Immunol Res. 2008;41(1):56-78.
6. Ciurea SO, Andersson BS. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(5): 523-536.
7. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89(9):3055-3060.
8. Gaziev J, Nguyen L, Puozzo C, Mozzi AF, Casella M, Perrone Donnorso M, et al. Novel pharmacokinetic behaviour of intravenous busulfan in children with tha-lassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood. 2010;115(22):4597-4604.
9. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002;8(9): 477-485.
10. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, et al. Association of busulfan area under the curve with veno-occlusive disease following HSCT. Bone Marrow Transplant. 1996;17 (2):225-230.
11. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet. 2000;39(2):155-165.
12. Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res. 1996;56(16):3678-3681.
13. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-trans-ferases alpha, mu, and pi. Drug Metab Dispos. 1996;24(9):1015-1019.
14. Poonkuzhali B, Chandy M, Srivastava A, Dennison D, Krishnamoorthy R. Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos. 2001;29(3):264-267.
15. Hassan M, Ljungman P, Ringdén O, Hassan Z, Oberg G, Nilsson C, et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant. 2000;25(9):915-924.
16. Almog S, Kurnik D, Shimoni A, Loebstein R, Hassoun E, Gopher A, et al. Linearity and stability of intravenous busulfan pharmaco-kinetics and the role of glutathione in busul-fan elimination. Biol Blood Marrow Transplant. 2011;17(1):117-123.
17. Lu SC. Regulation of glutathione synthesis. Mol Aspects Med. 2009;30(1-2):42-59.
18. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22(1):27-42.
19. Vaughan WP, Carey D, Perry S, Westfall AO, Salzman DE. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant. 2002;8(11):619-624.
20. Rifai N, Sakamoto M, Lafi M, Guinan E. Measurement of plasma busulfan concentration by high-performance liquid chromatog-raphy with ultraviolet detection. Therapeutic Drug Monitoring. 1997;19(2): 169-174.
21. Storci G, Sansone P, Mari S, D'Uva G, Tavolari S, Guarnieri T, et al. TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phe-notype. J Cell Physio. 2010;225(3):682-691.
22. Tregouet DA, Garelle V. A new JAVA interface implementation of THESIAS: Testing haplotype Effects In Association Studies. Bioinformatics. 2007;23(8):1038-1039.
23. Bearman SI. Toxicities of stem cell transplantation regimens. In: Atkinson K, Champlin R, Ritz J, Fibbe WE, Ljungman P and Brenner MK, eds. Clinical bone marrow and blood stem cell transplantation. Cambridge: Cambridge University Press; 2004. p.1301-1356.
24. Ning B, Wang C, Morel F, Nowell S, Ratnasinghe DL, Carter W, et al. Human glu-tathione S-transferase A2 polymorphisms: variant expression, distribution in prostate cancer cases/controls and a novel form. Pharmacogenetics. 2004;14(1):35-44.
25. Maekawa K, Hamaguchi T, Saito Y, Tatewaki N, Kurose K, Kaniwa N, et al. Genetic variation and haplotype structures of the glutathione S-transferase genes GSTA1 and GSTA2 in Japanese colorectal cancer patients. Drug Metab Pharmacokinet. 2011;26(6):646-658.
26. Coles BF, Morel F, Rauch C, Huber WW, Yang M, Teitel CH, et al. Effect of polymorphism in the human glutathione S-trans-ferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics. 2001;11(8):663-669.
27. Zhang W, Modén O, Mannervik B. Differences among allelic variants of human glutathione transferase A2-2 in the activation of azathioprine. Chem Biol Interact. 2010;186(2):110-117.
28. Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;45:51-88.
29. Pasparakis M. Regulation of tissue home-ostasis by NF-kappaB signalling: implications for inflammatory diseases. Nat Rev Immunol. 2009;9(11):778-788.
30. Kawase A, Tsunokuni Y, and Iwaki M. Effects of Alterations in CAR on Bilirubin Detoxification in Mouse Collagen-Induced Arthritis. Drug Metab Dispos. 2007;35(2): 256-261.
31. Assenat E, Gerbal-Chaloin S, Larrey D, Saric J, Fabre JM, Maurel P, et al. Interleukin 1beta inhibits CAR-induced expression of hepatic genes involved in drug and bilirubin clearance. Hepatology. 2004;40(4):951-960.
32. van de Steeg E, Stránecký V, Hartmannová H, Nosková L, Hřebíček M, Wagenaar E, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest. 2012;122(2):519-528.
33. Huang W, Zhang J, Chua SS, Qatanani M, Han Y, Granata R, et al. Induction of biliru-bin clearance by the constitutive androstane receptor (CAR). Proc Natl Acad Sci USA. 2003;100(7):4156-4161.
34. Landi S, Gemignani F, Neri M, Barale R, Bonassi S, Bottari F, et al. Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothe-lioma. Int J Cancer. 2007;120(12):2739-2743.
35. Goekkurt E, Stoehlmacher J, Stueber C, Wolschke C, Eiermann T, Iacobelli S, et al. Pharmacogenetic analysis of liver toxicity after busulfan/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation. Anticancer Res. 2007;27(6C): 4377-4380.
36. Tetlow N, Board PG. Functional polymorphism of human glutathione transferase A2. Pharmacogenetics. 2004;14(2):111-116.
37. Morel F, Rauch C, Coles B, Le Ferrec E, Guillouzo A. The human glutathione trans-ferase alpha locus: genomic organization of the gene cluster and functional characterization of the genetic polymorphism in the hGSTA1 promoter. Pharmacogenetics. 2002;12(4):277-286.
38. Kusama M, Kubota T, Matsukura Y, Matsuno K, Ogawa S, Kanda Y, et al. Influence of glu-tathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta. 2006;368(1-2):93-98.
39. Johnson L, Orchard PJ, Baker KS, Brundage R, Cao Q, Wang X, et al. Glutathione S-transferase A1 genetic variants reduce busul-fan clearance in children undergoing hematopoietic cell transplantation. J Clin Pharmacol. 2008;48(9):1052-1062.
40. Kim SD, Lee JH, Hur EH, Lee JH, Kim DY, Lim SN, et al. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(8):1222-1230.
41. Abassi N, Vadnais B, Knutson JA, Blough DK, Kelly EJ, O'Donnell PV, et al. Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. J Clin Pharmacol. 2011;51(10): 1429-1438.
42. Ansari M, Lauzon-Joset JF, Vachon MF, Duval M, Théoret Y, Champagne MA, et al. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Bone Marrow Transplant. 2010;45(2):261-267.
43. Zwaveling J, Press RR, Bredius RG, van Derstraaten TR, den Hartigh J, Bartelink IH, et al. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther Drug Monit. 2008; 30(4):504-510.
44. DeLeve LD, Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology. 2000;60(3):143-154.
45. Ferrà C, de Sanjosé S, Gallardo D, Berlanga JJ, Rueda F, Marìn D, et al. IL-6 and IL-8 levels in plasma during hematopoietic progenitor transplantation. Haematologica. 1998;83 (12):1082-1087.